Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Adjuvant Capital

Investor type Venture Capital
Founders Charlie Petty Glenn Rockman Kabeer Aziz

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 18
Average round size
info
The average size of a deal this fund participated in
$29M
Portfolio companies 16
Rounds per year 1.80
Lead investments 2
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.11
Exits 2
Key employees Soon
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Life Science
  • Genetics
Summary

Adjuvant Capital is the famous VC, which was founded in 2012. The leading representative office of defined VC is situated in the New York. The fund was located in North America if to be more exact in United States.

The important activity for fund was in 2019. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in 2-6 deals every year. Considering the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations.

The current fund was established by Charlie Petty, Glenn Rockman, Kabeer Aziz.

Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight X-Vax Technology, Themis Bioscience, InDevR. Among the most popular fund investment industries, there are Biotechnology, Health Care. The fund has exact preference in a number of founders of portfolio startups. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Adjuvant Capital, startups are often financed by aws Gru00fcnderfonds (aws Founders Fund), Wellington Partners, Ventech. The meaningful sponsors for the fund in investment in the same round are aws Gru00fcnderfonds (aws Founders Fund), Wellington Partners, Ventech.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Adjuvant Capital:
Typical Co-investors
Adjuvant Capital is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Adjuvant Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
efinanceworks New York, New York, United States
Encavis Germany, Hamburg
Food & Fun Ventures Florida, Palm Beach, United States
GMT Capital Atlanta, Georgia, United States
Granite Hacarmel HaMerkaz, Israel, Netanya
Harbor Pacific Capital China, Hong Kong, Hong Kong Island
Hyperion Israel Venture Partners -
Jia Zhong Guang Li Touzi Beijing, Beijing, China
Jinshan Capital Changsha, China, Jiangsu
Latitude Consultants Limited -
Responder Ventures Florida, United States, West Palm Beach
Scale Capital Chile, Region Metropolitana, Santiago
Seven Peaks Software Bangkok, Krung Thep, Thailand
Space3ac Gdansk, Poland, Pomorskie
Startup Labs California, San Francisco, United States
Tensility Venture Partners Chicago, Illinois, United States
Tuode Capital -
WERCBench Labs Milwaukee, United States, Wisconsin
Yingzhi (Yinchuan) Touzi Guanli Co., Ltd. -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Memo Therapeutics

Biotechnology
Collaboration
$25M16 Feb 2022 Zurich, Zurich, Switzerland

Curevo

Biopharma
Biotechnology
$60M07 Jan 2022 -

54gene

Biotechnology
Genetics
Health Care
Life Science
$25M16 Sep 2021 Washington, District of Columbia, United States

VitriVax

Biotechnology
Medical
Medical Device
Therapeutics
07 Jul 2021 Boulder, Colorado, United States

Pulmocide

Biotechnology
Drug Discovery
Health Care
Health Diagnostics
Medical
Medical Device
Pharmaceuticals
$92M27 May 2021 London, England, United Kingdom

Excision BioTherapeutics

Biotechnology
Health Care
Therapeutics
$60M17 Feb 2021 Philadelphia, Pennsylvania, United States

Frontier Nutrition

Consumer Goods
Manufacturing
Packaging Services
$6M03 Feb 2021 New Haven, Connecticut, United States

Excision BioTherapeutics

Biotechnology
Health Care
Therapeutics
02 Feb 2021 Philadelphia, Pennsylvania, United States

Univercells

Biotechnology
Health Care
Manufacturing
$23M17 Dec 2020 Charleroi, Hainaut, Belgium
News
African genomics startup 54gene raises $25M to expand precision medicine capabilities

– African genomics startup 54gene has raised $25m in Series B funding.
– Pan-African venture capital firm Cathay AfricInvest Innovation Fund led this round.
– Lead investor from the company’s Series A funding, Adjuvant Capital, invested once again with participation from other VCs including KdT Ventures, Plexo Capital, Endeavor Catalyst and Ingressive Capital.
– The company has raised a total of $45m since its inception.

YishengBio Raises $130 Million in Series B Funding to Accelerate Pipeline Development and Commercialization

– YishengBio announced that it has raised US$130m in Series B funding.
– The round was co-led by Oceanpine and OrbiMed.
– The company’s institutional investors include: OrbiMed, Oceanpine, EightRoad, F-Prime Capital, 3W Capital, Hillhouse Capital, Adjuvant Capital, MSA Capital, AIHC, Epiphron Capital, Superstring Capital, Haitong International, etc.
– The company is engaged in discovering, developing and commercializing innovative biotherapeutics for cancers and infectious diseases using novel PIKA® immunomodulating technology.
– The company operates in China, USA, and Singapore with over 500 employees.
– YSJA™ rabies vaccine is the first alum-free lyophilized rabies vaccine launched in China.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Adjuvant Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: